NanoViricides Inc represents innovation, dedication, and a commitment to combating viral infections. As a biopharmaceutical company, NanoViricides aims to develop antiviral therapeutics based on its proprietary nanomedicine platform. The company focuses on creating novel nanomedicines that can selectively target and destroy viruses, offering potential solutions for various infectious diseases. With its cutting-edge technology and research expertise, NanoViricides Inc strives to provide effective treatment options that address unmet medical needs. By harnessing the power of nanomedicine, the company aims to revolutionize the field of antiviral therapeutics, offering hope for patients worldwide.

NanoViricides Inc is primarily present in the United States, focusing on the research and development of nanomedicines for multiple diseases caused by viral infections. With headquarters in Connecticut, the company's operations span across different regions in the US.

NanoViricides Inc has achieved several significant milestones. Firstly, the company successfully completed the pre-IND (Investigational New Drug) meeting with the FDA for its drug candidate against COVID-19, indicating progress towards clinical trials. Additionally, NanoViricides has obtained orphan drug designation from the FDA for its drug candidate against shingles, which provides incentives for its development. The company has also demonstrated the effectiveness of its drug candidates against various viral infections in preclinical studies. Moreover, NanoViricides has received several patents for its innovative nanomedicine technologies, enhancing its intellectual property portfolio. These milestones showcase NanoViricides Inc's dedication to advancing antiviral therapeutics and positioning itself as a leader in the field.

NanoViricides Inc, founded in 2005, is a nano-biopharmaceutical company focused on developing innovative antiviral therapies. With its proprietary technology platform, the company aims to address unmet medical needs in viral infections. NanoViricides has a strong R&D team dedicated to advancing its nanomedicine candidates. Its cutting-edge technology enables the design and synthesis of nanoviricides, which can specifically target and destroy virus particles. This approach shows potential not only for direct antiviral therapy but also for disrupting the life cycle of viruses. NanoViricides Inc strives to contribute to improving public health by developing safe and effective therapeutics against a range of viral diseases.

NanoViricides Inc faces competition from several companies in the market. Some of the main competitors include AbbVie Inc., Gilead Sciences Inc., and Pfizer Inc. These companies also focus on developing antiviral drugs and therapeutics to address various viral diseases. While NanoViricides Inc specializes in nanomedicine-based treatments, AbbVie, Gilead Sciences, and Pfizer have a broader range of products and research areas. Competition in the market drives innovation and allows for a wider range of options for patients and healthcare providers.

NanoViricides Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of NanoViricides Inc revolves around the development and commercialization of nanomedicines designed to specifically combat various viral infections. With a focus on targeting infectious diseases that have limited or no effective treatment options, NanoViricides aims to utilize its unique nanomedicine technology to create innovative therapeutic solutions. By leveraging its expertise in nano-biophysics and pharmacology, the company strives to create antiviral drugs that can selectively and effectively neutralize viral pathogens. NanoViricides Inc aims to revolutionize the medical industry by pursuing the development of highly effective antiviral treatments to improve patient outcomes and combat global health threats.

NanoViricides P/E suhe on −2,07.

NanoViricides KUV on 0.

AlleAktien kvaliteediskoor ettevõttele NanoViricides on 2/10.

Praegu ei saa NanoViricides käivet arvutada.

oodatud NanoViricides kasum on −8,13 mln. USD.

NanoViricides Inc. is a biotechnology company specializing in the development of therapeutics against viruses. Their goal is to develop innovative technologies to combat viral diseases and provide effective treatment options for patients. The company is based in the USA and was founded in 2005. The business model of NanoViricides consists of different divisions: 1. Research and Development: This is the most important division of NanoViricides. The company is constantly searching for new compounds against different viruses. The goal is to develop drugs that are more effective, safer, and more efficient than existing antiviral therapeutics. 2. Production: NanoViricides has its own production department where the developed compounds are manufactured on a large scale. 3. Marketing: NanoViricides actively markets its products to increase visibility and attract customers. 4. Partnerships: NanoViricides collaborates with partners from the scientific and industrial sectors to develop a wider range of medications. NanoViricides offers various products and solutions that can be used for the treatment of viral diseases. Their key products include: 1. Nanoviricide® Technology: The Nanoviricide® Technology is a groundbreaking platform for the development of complex and highly specific antiviral compounds. This technology consists of specially designed nanoparticles that bind to specific receptors in the virus-infected organism to neutralize the infection. 2. Anti-Influenza Therapeutics: NanoViricides has developed a range of anti-influenza therapeutics that aim to eliminate influenza viruses within hours. These therapeutics have a very high binding affinity for influenza viruses. 3. Viral Eye Diseases: NanoViricides has also developed solutions for viral eye diseases such as conjunctivitis and herpetic keratitis. These products can be applied locally and have a high efficacy in combating viruses. NanoViricides continuously works on researching and developing new compounds against different viruses. The company has already made significant progress in the development of therapy options against influenza, HIV, dengue fever, Ebola, and other viral infections. Conclusion: NanoViricides Inc. is an innovative biotechnology company specializing in the development of antiviral therapeutics. The company has different divisions, such as research and development, production, marketing, and partnerships. Through the innovative Nanoviricide® Technology and the development of effective antiviral therapeutics, NanoViricides adopts groundbreaking approaches to combat viral infections and makes a significant contribution to improving the health of patients.

NanoViricides maksab dividendi 0 USD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu NanoViricides jaoks arvutada või ettevõte ei maksa dividende välja.

NanoViricides ISIN on US6300873022.

NanoViricides WKN on A2PSNF.

NanoViricides tähis on NNVC.

Viimase 12 kuu jooksul maksis NanoViricides dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab NanoViricides tõenäoliselt dividendi summas 0 USD.

NanoViricides praegune dividenditootlus on .

NanoViricides maksab kvartaalset dividendi. See makstakse välja kuudel .

NanoViricides maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 USD. See vastab dividenditootlusele 0 %.

NanoViricides on liigitatud sektorisse 'Tervis'.

Viimase NanoViricides dividendide saamiseks 28.9.2024 suuruses 0 USD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 28.9.2024.

Viimane dividendimakse toimus 28.9.2024.

Aastal 2023 maksis NanoViricides 0 USD dividende.

NanoViricides dividendid makstakse välja USD.